Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Depreciation: 2015-2023

Historic Accumulated Depreciation for Editas Medicine (EDIT) over the last 7 years, with Jun 2023 value amounting to $23.5 million.

  • Editas Medicine's Accumulated Depreciation rose 26.38% to $23.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $23.5 million, marking a year-over-year increase of 26.38%. This contributed to the annual value of $21.5 million for FY2022, which is 38.81% up from last year.
  • Per Editas Medicine's latest filing, its Accumulated Depreciation stood at $23.5 million for Q2 2023, which was up 6.98% from $22.0 million recorded in Q1 2023.
  • In the past 5 years, Editas Medicine's Accumulated Depreciation registered a high of $23.5 million during Q2 2023, and its lowest value of $5.1 million during Q1 2019.
  • Over the past 3 years, Editas Medicine's median Accumulated Depreciation value was $17.8 million (recorded in 2022), while the average stood at $17.7 million.
  • Data for Editas Medicine's Accumulated Depreciation shows a peak YoY surged of 56.40% (in 2020) over the last 5 years.
  • Over the past 5 years, Editas Medicine's Accumulated Depreciation (Quarterly) stood at $7.2 million in 2019, then skyrocketed by 54.01% to $11.1 million in 2020, then spiked by 39.77% to $15.5 million in 2021, then surged by 38.81% to $21.5 million in 2022, then climbed by 26.38% to $23.5 million in 2023.
  • Its last three reported values are $23.5 million in Q2 2023, $22.0 million for Q1 2023, and $21.5 million during Q4 2022.